Received Dec 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | 3342056-4250 | OT / LA |
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE) | SANOFI PASTEUR | 1 | 3342057-4250 | — |
| RSV | RSV (ABRYSVO) | PFIZER\WYETH | 1 | 3342059-4250 | — |
he developed plaque psoriasis afterwards; This is a spontaneous report received from an Other HCP and a Consumer or other non HCP, Program ID. A 67-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 09Oct2023 as dose 1, single (Lot number: 3342056-4250) at the age of 67 years intramuscular, in left arm for covid-19 immunisation; rsv vaccine prot.subunit pref 2v (ABRYSVO), on 09Oct2023 as dose 1, single (Lot number: 3342059-4250) at the age of 67 years, in arm for immunisation; influenza vaccine inact split 3v (FLUZONE SENIOR), on 09Oct2023 as dose 1, single (Lot number: 3342057-4250), in arm for immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, single; unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (Dose 2, single; unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (Dose 3, single; unknown manufacturer), for COVID-19 immunization. The following information was reported: PSORIASIS (non-serious), outcome "unknown", described as "he developed plaque psoriasis afterwards". Additional information: it was reported that the patient was administered all 3 vaccines (Abrysvo, Comirnaty, Fluzone HF65+) in the same time, and he developed plaque psoriasis afterwards.